Behavioral health clinicians are often the first person a patient tells about a regenerative medicine decision, and the only one who hears the hope attached to it. This psychiatrist adipose banking guide is about that conversation rather than about cells, and about how to explore a patient’s expectations without dismissing them.
TLDR: Patients often raise regenerative medicine with their psychiatrist rather than with the specialist managing the condition, and the useful response is neither endorsement nor dismissal. Ask what the patient expects to be different, then verify it together using FDA’s consumer alert, the warning letters database, and the status of any cited trial. No adipose-derived product is FDA approved for any condition. Banking is storage, and it does not guarantee eligibility, access, or clinical benefit.
Important Disclaimer: Save My Fat is a connector linking patients and providers to a United States tissue bank. Save My Fat does not provide FDA-approved treatments or cures and does not guarantee eligibility, access, or clinical benefit. No adipose-derived product is FDA approved for any psychiatric, behavioral, or neurologic condition. This article is for clinicians for educational purposes only and is not clinical or legal advice, and patients should consult their own licensed healthcare professionals before deciding about banking.
A patient raises it near the end of the session. They have been reading about regenerative medicine, there is a clinic within driving distance, and they want to know what you think. They are not asking for a referral. They are asking whether it is reasonable to hope.
That question lands in behavioral health more often than in the specialty that owns the condition, because patients ask the clinician who has time. Correcting the record fast is understandable and usually counterproductive. A patient who feels dismissed stops telling you about it.
What the Advertising Offers, and Who It Reaches
Strip away the design and most regenerative medicine marketing offers three things: a biological explanation after years of ambiguity, a definite action after a long wait, and a short timeline. That is powerful for a patient told to keep waiting.
FDA’s consumer alert on regenerative products lists conditions these products are marketed for without approval, and several sit inside or beside behavioral health practice. Read that list as a map of where the advertising goes, never as a research lead. The alert states that blood-forming stem cells from cord blood are the only approved stem cell products.
Enforcement follows the same pattern. FDA’s August 2025 letter to Innate Healthcare Institute cited an umbilical cord cell product for non-homologous use that included an intended treatment of autism. That is a finding about advertising. Nothing in it suggests these products do anything for autism or any behavioral health condition.
Interest in these clinics is usually rational given what the patient has been shown, not a symptom to manage. Chronic illness produces a particular fatigue, and the patient becomes the difficult case whose file keeps growing. Testimonials supply social proof, and a large payment converts a passive patient into an active agent. The background on hope and placebo effect covers how much reported improvement arrives before any biology does.
How to Discuss Stem Cell Banking With Patients Without Dismissing Them
The opening question is not whether the clinic is legitimate. It is what the patient expects to be different. Most patients are not in crisis, some are, and telling those apart is worth doing deliberately.
Start With the Expected Change
Ask what would be different in six months if this went as well as they hope. Ask what they were told, by whom, and in what form. Ask what a disappointing result would look like, and what the plan becomes if nothing changes. Patients who cannot answer those last two are holding a feeling rather than weighing a decision.
Choose Language That Keeps the Door Open
Word choice decides whether the next conversation happens. Dismissal and enthusiasm both end it, one by pushing the patient away and the other by lending your credibility to something you cannot vouch for. The table pairs common responses with accurate alternatives.
| A common response | A version that keeps the conversation open |
|---|---|
| That is a scam. | Let us look at what they offer and check it together. |
| There is no evidence for that. | Nothing like that is FDA approved, and I can show you how to check the trials. |
| It might help. Who knows. | Outcomes cannot be predicted and individual results vary. |
| That is not my area. | It is not, so take these links to the clinician managing the condition. |
None of these concede anything factual or withdraw support. That makes patient anxiety about stem cell decisions workable rather than adversarial.
Two Verified Results Worth Keeping in Your Pocket
Two specific findings do more work here than general statements about weak evidence.
ADIPOA2 was a randomized phase 2b trial of autologous adipose-derived cells injected into the knee for mild to moderate osteoarthritis. At six months, 47.3 percent of the cell arm and 54.8 percent of the placebo arm met the strict responder definition, with a P value of.46. The published ADIPOA2 results, covering 97 analyzed patients, concluded that the injection “did not significantly improve pain and function.”
NCT04371393 was a phase 3 trial of an allogeneic bone marrow derived product, not an adipose product, in severe COVID-19 respiratory distress with 223 participants. It was terminated after the data monitoring board halted randomization “due to low predictive probability of achieving postulated mortality benefit.” Neither result supports any claim of benefit, the evidence here is preliminary, and the decision belongs with the treating clinician.
Verification Steps You Can Hand a Patient in One Visit
Four checks take about twenty minutes and need no medical training. First, read the FDA consumer alert in full. Second, search the FDA warning letters database for the clinic, company, and physician names. Third, check FDA’s list of approved cellular and gene therapy products and confirm no adipose-derived product appears. Fourth, find the trial number the clinic cites and read its status.
What Unknown and Terminated Actually Mean
The fourth step fails most often, because clinic websites cite registry listings as though registration were approval. Registration is a requirement, not a credential. The statuses below come from the registry glossary.
| Status | Definition as published by the registry |
|---|---|
| Recruiting | “The study is currently recruiting participants.” |
| Terminated | “The study has stopped early and will not start again. Participants are no longer being examined or treated.” |
| Unknown | Last known status was recruiting or active not recruiting, and the record passed its completion date without verification for 2 years. |
Terminated means a study stopped early and will not restart, which is not the same as finished. Unknown, per the ClinicalTrials.gov glossary, means nobody has checked the record in two years.
What State Law Requires a Patient to Be Told
Several states now require a specific notice in advertising and in the office. Florida’s reads: “THIS NOTICE MUST BE PROVIDED TO YOU UNDER FLORIDA LAW. This physician performs one or more stem cell therapies that have not yet been approved by the United States Food and Drug Administration. You are encouraged to consult with your primary care provider before undergoing any stem cell therapy.”
Georgia and Tennessee adopted similar notices effective July 1, 2026, each paired with a signed consent form. Florida’s took effect July 1, 2025 and limits these therapies to orthopedics, wound care, or pain management. Utah requires forty point type, posted where patients can see it.
The notice tells patients to consult their primary care provider, and many consult you instead, which is how a psychiatrist ends up inside this decision. It also reaches only as far as the law does, so a patient looking overseas may see nothing.
Psychiatrist Adipose Banking Versus Treatment
Patients routinely merge two separate decisions, and separating them lowers the temperature. Banking is storage. Tissue is collected during a procedure the patient is already having, sent to a laboratory, and preserved. Treatment is a different decision, made later, under a different regulatory status.
Banking does not create eligibility, access, or benefit, and it does not connect anyone to a treatment pathway. Save My Fat is a connector to a tissue bank and does not collect, process, store, or treat. The survey of what patients believe gives the patient-side picture, and the guidance on introducing banking to patients keeps the discussion on storage.
Frequently Asked Questions
Why would a psychiatrist or behavioral health provider need to know about adipose banking?
Because you are often the clinician the patient tells first. Behavioral health visits run longer, the relationship is older, and the patient has already disclosed what has not worked. You need no technical expertise, only enough orientation to ask good questions.
How can providers address patient anxiety or unrealistic expectations about regenerative medicine?
Start with the expected change rather than the evidence. Ask what would be different, what a disappointing result would look like, and what happens if nothing shifts. Then verify together using the FDA consumer alert, the warning letters database, and the status of any cited trial.
What should a mental health provider say if a patient asks about banking as a hope-based decision?
Take the hope seriously and keep the facts intact. Banking is storage of the patient’s own tissue and nothing more. It does not guarantee eligibility, access, or clinical benefit, and no adipose-derived product is FDA approved. If the patient is buying reassurance, name that gently.
How does hype in regenerative medicine marketing affect patient psychology?
It supplies certainty where medicine has offered ambiguity, which pulls hard on someone with a long illness course. Testimonials work as social proof, a mechanism story restores cause and effect, and a large payment converts passivity into action. Reported improvement can arrive before any biological change.
What compliant language helps set realistic expectations in these conversations?
Use accurate, non-promissory phrasing. Outcomes cannot be predicted and individual results vary. Evidence is preliminary and more studies are needed. Nothing on offer is FDA approved, and any future use depends on regulatory status and physician judgment. Document the conversation.
What should I do if a patient has already paid for treatment at a clinic?
Do not lead with the mistake. Ask what they experienced, what they expected, and what they would tell someone considering it now. Keep the relationship intact so the next decision includes you. Route any adverse event to their treating physician promptly.
Key Takeaways
Behavioral health stem cell banking conversations are expectation conversations, not scientific ones, and the clinician who stays in the room is more useful than the one who is right first. Ask what the patient expects to be different and what happens if nothing changes. Then hand over a method rather than a verdict: the FDA consumer alert, the warning letters database, the approved product list, and the status of any cited trial.
ADIPOA2 showed a numerically higher responder rate in the placebo arm, and NCT04371393 was halted for low predictive probability of benefit. Advertising notices in Georgia, Tennessee, Florida, and Utah tell patients to consult a physician, and many consult you instead. Banking is storage, and it does not guarantee eligibility, access, or clinical benefit.
Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, California, Georgia, and Tennessee governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Clinicians whose patients ask about adipose tissue banking for potential future use can review current pricing, and questions can go to the Save My Fat team.
Save My Fat works with a U.S.-based tissue bank for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including psychiatry input is required before publication. Please consult your psychiatrist before making any decisions about banking, treatment, or research participation.
About the author: Oscar Tellez is the founder and CEO of Save My Fat. He holds a Bachelor of Science in Exercise Science and Health Promotion from Florida Atlantic University. He has spent more than a decade in the regenerative medicine industry across product distribution, laboratory and vendor relationships, and provider training. He is not a licensed clinician, and this article is educational, not medical advice.
Related guide: the physician resource center.
